This Phase 2 trial
was an open-label, single-arm, multi-center study of talabostat and cisplatin with Stage IV melanoma.
This press release contains forward-looking statements regarding the implications of the results of the company's Phase 1 combination therapy trial with ARQ 501 and the planned initiation of Phase 2 trials
with ARQ 501.
Based on the preliminary phase 1 results, the Company announced today the start of a 150 patient, 12 week, phase 2 trial
of the VEGF Trap in wet AMD.
Additional analysis of the Phase 2 trial
data will be presented by Biovest at the American Society for Hematology meeting.
The additional NSCLC Phase 2 trial
results will be presented in detail at an upcoming poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on Wednesday, November 16, 2005.
This second Phase 2 trial
is being conducted in order to gain a greater understanding of safety and tolerability of INS37217 Respiratory in a broader population of CF patients, which may allow expansion of the patient population for the upcoming Phase 3 trial.
Inotek Pharmaceuticals Corporation announced today that it has commenced enrollment in a Phase 2 trial
for its lead compound, INO-1001, for the prevention of cardiac necrosis (heart damage) in patients undergoing emergent angioplasty after an acute myocardial infarction.
We believe in the approvability of our eCTD application based upon the most recent 36-month follow-up data from the MP-US-M01 Phase 3 trial (M01) in patients with advanced malignant melanoma coupled, with the single-arm MP-MA-0103 Phase 2 trial
(M0103) reported earlier this year.
Patient enrollment has been completed in three Phase 2 trials
with ARQ 501.